Published on: April 7, 2026

PRISM BioLab announces that Eisai Co., Ltd. will present preclinical research results for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the American Association for Cancer Research (AACR) Annual Meeting 2026 from April 17 to 22, 2026. The abstract of the study has been disclosed.

For more details, please click here